ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

3:00PM-4:30PM: Abstract Number: 0852

3-dimensional Shape Changes of the Knee over 4 Years Are Linear and Progressive but Much More Rapid in Osteoarthritic Joints: Data from the Osteoarthritis Initiative

Abstracts: Imaging of Rheumatic Diseases

3:00PM-4:30PM: Abstract Number: 0830

Activation of Autoreactive Lymphocytes in the Lung by STING Gain-of-function Mutation Expressing Radioresistant Cells

Abstracts: Pediatric Rheumatology – Basic Science

3:00PM-4:30PM: Abstract Number: 0855

Addition of Immunosuppressive Agents And/or Intravenous Immunoglobulin to Steroids in the Treatment of Susac Syndrome: A National Cohort Study

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

3:00PM-4:30PM: Abstract Number: 0850

Assessment of Correlation Between Composite Ultrasonographic Index (ECODAS) and Disease Activity Score 28 in Patients with Rheumatoid Arthritis

Abstracts: Imaging of Rheumatic Diseases

3:00PM-4:30PM: Abstract Number: 0868

Autoantibodies to Joint-related Proteins Predict Severe Joint Destruction in Difficult-to-treat Rheumatoid Arthritis Patients

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Bad Blood (Serologic and Imaging Biomarkers)

3:00PM-4:30PM: Abstract Number: 0858

Baricitinib in Early Polymyalgia Rheumatica (BACHELOR Study)

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

3:00PM-4:30PM: Abstract Number: 0837

Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome

Abstracts: Antiphospholipid Syndrome

3:00PM-4:00PM: Abstract Number: PP15

Breathing Mindfully and How to Control Anxiety in Lupus Patients

Patient Perspectives

3:00PM-4:00PM: Abstract Number: PP13

Bridging the Gap from Pediatric to Adult Rheumatology Care

Patient Perspectives

3:00PM-4:30PM: Abstract Number: 0876

C-CAR168 as a Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy for the Treatment of Autoimmune Diseases

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

3:00PM-4:30PM: Abstract Number: 0841

Clinical and Biologic Predictors of Thrombosis in Persistently Antiphospholipid Antibody Positive Patients: Prospective Analysis of the International APS ACTION Clinical Database and Repository (“Registry”)

Abstracts: Antiphospholipid Syndrome

3:00PM-4:30PM: Abstract Number: 0856

Comparative Effectiveness of Disease Modifying Antirheumatic Drugs for Cardiac Sarcoidosis

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

3:00PM-4:30PM: Abstract Number: 0839

Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity

Abstracts: Antiphospholipid Syndrome

3:00PM-4:30PM: Abstract Number: 0866

Cross-sectional Analysis of Erosive Hand Osteoarthritis and Fracture Risk

Abstracts: Osteoarthritis – Novel Insights from Observational Studies

3:00PM-4:30PM: Abstract Number: 0869

Deciphering Pathogenic Phenotypes by Multi-modal Deep Single-cell Blood Immunophenotyping in Individuals At-risk for Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Bad Blood (Serologic and Imaging Biomarkers)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].